Literature DB >> 10508982

Different molecular basis for spinal muscular atrophy in South African black patients.

G Stevens1, T Yawitch, J Rodda, S Verhaart, A Krause.   

Abstract

Spinal muscular atrophy (SMA) is an autosomal recessive disorder occurring at a rate of between 1/5,000 and 1/10,000 births in most European countries. The phenotype results from the degeneration of the anterior horn cells of the spinal cord, resulting in symmetrical muscle weakness and wasting. The disorder can be classified according to the severity of the disease and the age of onset into three major types. Two candidate SMA genes, NAIP and SMN, isolated from the 5q13 region, have been reported to be homozygously deleted in approximately 30% and >95% of SMA patients, respectively. Black SMA patients have been reported to have facial muscle weakness more commonly. This study aimed to determine the molecular basis of SMA in South African black SMA patients. The SMN gene was found to be homozygously deleted in 65.5% (19/29) of patients, significantly less frequently than in previous studies. Similarly, the NAIP gene was homozygously deleted in a smaller number, 14% (4/29) of patients; 47% (9/19) of SMN deletion patients appeared to have deletions of telomeric exon 7, but not exon 8. In at least six of these patients a gene conversion event has occurred. No detectable deletions were found in 35% (10/29) of patients. Haplotype analysis in the nondeletion patients, using six closely linked markers, provided no evidence for a founder mutation. No mutations were found in exons 3 and intron 6 through exon 8 by sequence analysis of these nondeletion patients. It is proposed that the differences in the SMA phenotype observed in black patients may in part be explained by a different molecular basis. Copyright 1999 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10508982

Source DB:  PubMed          Journal:  Am J Med Genet        ISSN: 0148-7299


  6 in total

1.  NCALD Antisense Oligonucleotide Therapy in Addition to Nusinersen further Ameliorates Spinal Muscular Atrophy in Mice.

Authors:  Laura Torres-Benito; Svenja Schneider; Roman Rombo; Karen K Ling; Vanessa Grysko; Aaradhita Upadhyay; Natalia L Kononenko; Frank Rigo; C Frank Bennett; Brunhilde Wirth
Journal:  Am J Hum Genet       Date:  2019-06-20       Impact factor: 11.025

2.  An approximately 140-kb deletion associated with feline spinal muscular atrophy implies an essential LIX1 function for motor neuron survival.

Authors:  John C Fyfe; Marilyn Menotti-Raymond; Victor A David; Lars Brichta; Alejandro A Schäffer; Richa Agarwala; William J Murphy; William J Wedemeyer; Brittany L Gregory; Bethany G Buzzell; Meghan C Drummond; Brunhilde Wirth; Stephen J O'Brien
Journal:  Genome Res       Date:  2006-08-09       Impact factor: 9.043

3.  Study of survival of motor neuron (SMN) and neuronal apoptosis inhibitory protein (NAIP) gene deletions in SMA patients.

Authors:  Akanchha Kesari; Usha Kant Misra; Jayantee Kalita; Vijay Nath Mishra; Sunil Pradhan; Siddramappa Jagdish Patil; Shubha Rajender Phadke; Balraj Mittal
Journal:  J Neurol       Date:  2005-03-18       Impact factor: 4.849

4.  Junctophilin 3 (JPH3) expansion mutations causing Huntington disease like 2 (HDL2) are common in South African patients with African ancestry and a Huntington disease phenotype.

Authors:  Amanda Krause; Claire Mitchell; Fahmida Essop; Susan Tager; James Temlett; Giovanni Stevanin; Christopher Ross; Dobrila Rudnicki; Russell Margolis
Journal:  Am J Med Genet B Neuropsychiatr Genet       Date:  2015-06-16       Impact factor: 3.568

Review 5.  Motor Neuron Diseases in Sub-Saharan Africa: The Need for More Population-Based Studies.

Authors:  Emmanuel Quansah; Thomas K Karikari
Journal:  Biomed Res Int       Date:  2015-08-12       Impact factor: 3.411

Review 6.  A review of the genetic spectrum of hereditary spastic paraplegias, inherited neuropathies and spinal muscular atrophies in Africans.

Authors:  Amokelani C Mahungu; Nomakhosazana Monnakgotla; Melissa Nel; Jeannine M Heckmann
Journal:  Orphanet J Rare Dis       Date:  2022-03-24       Impact factor: 4.123

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.